Batool Shannan
Overview
Explore the profile of Batool Shannan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
548
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Placke J, Bottek J, Varaljai R, Shannan B, Scharfenberg S, Krisp C, et al.
Br J Dermatol
. 2024 Dec;
192(3):481-491.
PMID: 39739311
Background: The tumour microenvironment significantly influences the clinical response of patients to therapeutic immune checkpoint inhibition (ICI), but a comprehensive understanding of the underlying immune-regulatory proteome is still lacking. Objectives:...
2.
Varaljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht L, Shannan B, et al.
Nat Cancer
. 2023 Aug;
4(9):1395.
PMID: 37580519
No abstract available.
3.
Varaljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht L, Shannan B, et al.
Nat Cancer
. 2023 Jul;
4(9):1292-1308.
PMID: 37525015
Recent studies suggest that BRAF-mutated melanomas in particular respond to dual anti-programmed cell death protein 1 (PD-1) and anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) immune checkpoint inhibition (ICI). Here we...
4.
Stejerean-Todoran I, Zimmermann K, Gibhardt C, Vultur A, Ickes C, Shannan B, et al.
EMBO Rep
. 2022 Sep;
23(11):e54746.
PMID: 36156348
Melanoma is the deadliest of skin cancers and has a high tendency to metastasize to distant organs. Calcium and metabolic signals contribute to melanoma invasiveness; however, the underlying molecular details...
5.
Chauvistre H, Shannan B, Daignault-Mill S, Ju R, Picard D, Egetemaier S, et al.
Nat Commun
. 2022 Jun;
13(1):3055.
PMID: 35650266
Melanoma is a highly plastic tumor characterized by dynamic interconversion of different cell identities depending on the biological context. Melanoma cells with high expression of the H3K4 demethylase KDM5B (JARID1B)...
6.
Varaljai R, Wistuba-Hamprecht K, Seremet T, Diaz J, Nsengimana J, Sucker A, et al.
JCO Precis Oncol
. 2020 Sep;
3.
PMID: 32914028
Purpose: Circulating cell-free tumor DNA (ctDNA) reflects the heterogeneous spectrum of tumor-specific mutations, especially in systemic disease. We validated plasma-based assays that allow the dynamic quantitative detection of ctDNA as...
7.
Vogel F, Bordag N, Zugner E, Trajkovic-Arsic M, Chauvistre H, Shannan B, et al.
J Invest Dermatol
. 2019 Jun;
139(12):2506-2516.e10.
PMID: 31229500
Melanoma cells shift between epigenetic-metabolic states to adapt to stress and, particularly, to drugs. Here, we unraveled the metabolome of an H3K4 demethylase (KDM5B/JARID1B)-driven melanoma cell phenotype that is known...
8.
Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, et al.
Cell Rep
. 2017 Nov;
21(7):1953-1967.
PMID: 29141225
Therapy of advanced melanoma is changing dramatically. Following mutational and biological subclassification of this heterogeneous cancer, several targeted and immune therapies were approved and increased survival significantly. To facilitate further...
9.
Garman B, Anastopoulos I, Krepler C, Brafford P, Sproesser K, Jiang Y, et al.
Cell Rep
. 2017 Nov;
21(7):1936-1952.
PMID: 29141224
Tumor-sequencing studies have revealed the widespread genetic diversity of melanoma. Sequencing of 108 genes previously implicated in melanomagenesis was performed on 462 patient-derived xenografts (PDXs), cell lines, and tumors to...
10.
Shannan B, Watters A, Chen Q, Mollin S, Dorr M, Meggers E, et al.
Oncotarget
. 2016 Jul;
7(34):54897-54912.
PMID: 27448973
Therapeutic strategies for the treatment of metastatic melanoma show encouraging results in the clinic; however, not all patients respond equally and tumor resistance still poses a challenge. To identify novel...